Matrizyme Pharma Corporation has developed MZ-004, an innovative therapy to facilitate angioplasty in patients suffering from Chronic Total Occlusions. These 100% complete blockages of an artery represent a significant under-served market due to their complexity and high rate of treatment failure.
Member count: 11-50
Investors 1
| Date | Name | Website |
| - | CPOINT Cap... | cpointcapi... |